Skip to content

Rheumatoid arthritis — biomarkers and tissue precision

TL;DR — RA has clinically useful biomarkers for classification and prognosis—ACPA, RF, CRP/ESR and imaging—but no validated molecular test reliably chooses the best DMARD mechanism for an individual. R4RA embedded synovial biopsy in a 164-patient randomized trial after TNF failure and found that low/absent synovial B-cell molecular signatures were associated with lower rituximab than tocilizumab response, an important proof of design rather than a ready-to-use companion diagnostic (Humby 2021, PMID 33485455; Rivellese 2022, PMID 35589854). A live PubMed search on 2026-08-30 found biopsy-stratified trials and biomarker analyses but no randomized clinical-utility trial comparing biomarker-guided selection with standard selection; STRAP and R4RA remain evidence of feasibility and interaction signals, not validated routine deployment (Rivellese 2023, PMID 38251532). A predictive biomarker must improve decisions over clinical variables; correlation with disease activity is not enough.

Biomarker jobs

Job Existing tools State of evidence
Susceptibility HLA, polygenic scores Research; poor individual specificity
Preclinical risk ACPA/RF, symptoms, MRI/US Enrichment useful; calibration limited
Classification ACPA, RF, ESR/CRP Incorporated in 2010 criteria
Prognosis Serology, erosions, activity Group-level structural risk
Activity CRP/ESR, joint counts, imaging Useful but treatment/mechanism sensitive
Treatment selection Clinical comorbidity; exploratory tissue/blood signatures No routine molecular selector
Remission depth Clinical composite; imaging/tissue research Reviews describe candidate molecular states, but no prospectively validated taper-selection test (Bhamidipati 2022, PMID 35248489)
Safety CBC, liver, renal, lipids, infection screening Established monitoring biomarkers

ACPA and rheumatoid factor

ACPA is more specific than RF and may precede arthritis for years. Titer, isotype, epitope breadth and glycosylation carry research information beyond positivity, but assays are not standardized for treatment selection (Atzeni 2017, PMID 28825772; van Heemst 2014, PMID 24813459).

Seropositive and seronegative RA differ in HLA association and clinical/synovial phenotype. Using serostatus as a stratifier is reasonable; assuming two uniform diseases is not (Perera 2024, PMID 38727279).

Acute-phase reactants and composite activity

CRP/ESR quantify systemic inflammation but are nonspecific. IL-6 receptor blockade and JAK inhibition can suppress CRP disproportionately to residual joint findings. Obesity, anemia, age and infection affect markers. A normal result cannot exclude synovitis.

Imaging biomarkers

Modality/feature Potential use Evidence boundary
Ultrasound power Doppler Objective vascular synovitis Operator/threshold variability
Ultrasound tenosynovitis At-risk/early disease enrichment Specificity not absolute
MRI synovitis Sensitive tissue inflammation Common low-grade findings
MRI osteitis Structural-progression risk Cost and access
Radiographic erosion Cumulative structural phenotype Late and insensitive to current activity

Imaging predicts progression in unclassified arthritis, but imaging-guided escalation has not improved outcomes over clinical T2T (de Pablo 2022, PMID 34782180; Mandl 2019, PMID 31518423).

Synovial biopsy

Biopsy directly samples the target organ. Ultrasound-guided needle and portal-and-forceps techniques enable multicenter collection, yet small tissue samples may miss spatially heterogeneous lesions.

Requirement for clinical translation Current gap
Reproducible acquisition Operator/site differences
Stable pathotype Tissue changes with time and therapy
Fast assay Research pipelines are slow
Prespecified cutoff Many signatures are data-derived
Treatment interaction Few randomized biomarker trials
Incremental utility Must beat clinical/comorbidity selection
Cost-effectiveness Biopsy and molecular analysis add burden

R4RA compared rituximab and tocilizumab after TNF failure. The primary histologic B-cell classification did not provide a simple universal selector; RNA-based B-cell signatures were more discriminating in analyses (Humby 2021, PMID 33485455; Rivellese 2022, PMID 35589854).

Blood multi-omics

Transcriptomics, proteomics, metabolomics, epigenetics and cell profiling can generate response signatures. A 2025 longitudinal cohort included 278 RA patients, 60 at-risk individuals and 99 controls and identified plasma protein patterns associated with onset, activity thresholds and treatment response; external prospective decision testing remains required (He 2025, PMID 40691443).

Pharmacogenetic methotrexate studies have not produced a broadly adopted selector (Ling 2020, PMID 31849277). Calprotectin correlates with inflammation and may predict response in some settings, but assay and comparator validation are incomplete (Caproli 2023, PMID 37584369).

Predictive versus prognostic evidence

Finding Meaning
Marker correlates with response in one treatment arm Prognostic or pharmacodynamic; not necessarily predictive
Marker differs between responders and nonresponders Vulnerable to confounding and overfitting
Marker × randomized treatment interaction Evidence for treatment selection
External prospective replication Transportability
Biomarker-guided trial improves outcomes Clinical utility

Performance thresholds and the precision-medicine test

Candidate Quantitative evidence Decision status
14-3-3η Meta-analysis found diagnostic discrimination beyond a single cohort, but with threshold and spectrum heterogeneity (Wang 2020, PMID 32909672). Adjunctive candidate; not a replacement for clinical synovitis, ACPA, or RF.
Multi-biomarker disease activity Age, sex, and adiposity materially alter the score, prompting a recalibrated formulation (Curtis 2019, PMID 30590790). A biologically plausible activity measure whose calibration and added decision value remain contested.
MRI osteitis/synovitis Both independently predicted later radiographic progression in early RA (Bøyesen 2011, PMID 20810395); sequential MRI edema and power-Doppler signal also enriched progression risk under treat-to-target (Takatani 2023, PMID 35856575). Prognostic association does not justify imaging-driven escalation when strategy trials show no net benefit.
Anti-TNF laboratory predictors Systematic review found many candidates but insufficient replicated, clinically deployable prediction (Wientjes 2022, PMID 36597975). No blood test reliably chooses a TNF inhibitor over another mechanism.
Adalimumab concentration Exploratory randomized-trial analyses identified a therapeutic concentration range associated with response (Gehin 2024, PMID 39537558). Association does not establish that proactive concentration-guided dosing improves outcomes or cost.
Synovial pathobiology STRAP/STRAP-EU prospectively tested biopsy-based stratification across biologics (Rivellese 2023, PMID 38251532). Tissue signals are real, but the primary clinical case for routine biopsy-guided selection remains incomplete.
Multi-omics remission Transcriptomic, proteomic, and immune-cell profiles approached healthy controls with treatment while resistant signatures persisted (Tasaki 2018, PMID 30013029). “Molecular remission” lacks a validated target threshold and intervention algorithm.

Prognostic and predictive evidence must be separated. Smoking and HLA-DRB1 position 11 relate to structural severity through ACPA-linked pathways (de Rooy 2014, PMID 24389296; van Steenbergen 2015, PMID 25580908), but neither demonstrates a treatment-by-marker interaction. A broad assessment of early-RA prediction models found recurrent risk-of-bias, inconsistent outcomes and limited external validation (Archer 2018, PMID 30501821). The controversy is therefore evidentiary: increasingly reproducible biology has not yet crossed the harder threshold of improving a randomized clinical decision.

Evidence map

This map adds directly adjacent evidence used to bound interpretation. Inclusion means the record informs this topic or a tightly linked decision; it does not imply that every study supports every conclusion on the page.

Adjacent evidence Relevance to this page
Jang S, et al. Pathogenic roles of diverse immune cells in RA. Int J Mol Sci. 2022. (PMID 35055087) Adjacent evidence from biologic-dmards.md, classification-and-diagnosis.md, epidemiology-and-burden.md, jak-inhibitors-and-targeted-therapy.md, overview.md, synovial-immunobiology.md
Cheng L, et al. New insights from single-cell sequencing: synovial fibroblasts and macrophages in RA. Front Immunol. 2021. (PMID 34349767) Adjacent evidence from biologic-dmards.md, jak-inhibitors-and-targeted-therapy.md, synovial-immunobiology.md
Knab K, et al. Synovial macrophage and fibroblast heterogeneity in joint homeostasis and inflammation. Front Immunol. 2022. (PMID 35547214) Adjacent evidence from biologic-dmards.md, jak-inhibitors-and-targeted-therapy.md, synovial-immunobiology.md
Kemble S, et al. Critical role of synovial tissue-resident macrophage and fibroblast subsets. Front Immunol. 2021. (PMID 34539648) Adjacent evidence from biologic-dmards.md, jak-inhibitors-and-targeted-therapy.md, synovial-immunobiology.md
Pap T, et al. Role of synovial fibroblasts in RA pathogenesis. Arthritis Res. 2000. (PMID 11094449) Adjacent evidence from biologic-dmards.md, jak-inhibitors-and-targeted-therapy.md, synovial-immunobiology.md
Komatsu N, et al. Mechanisms of joint destruction in RA: immune cell-fibroblast-bone interactions. Nat Rev Rheumatol. 2022. (PMID 35705856) Adjacent evidence from synovial-immunobiology.md
Matsuda K, et al. Synovial fibroblasts leading to joint destruction in RA. Int J Mol Sci. 2023. (PMID 36982247) Adjacent evidence from synovial-immunobiology.md
Lipsky PE, et al. Infliximab and methotrexate in rheumatoid arthritis. N Engl J Med. 2000. (PMID 11096166) Adjacent evidence from biologic-dmards.md, classification-and-diagnosis.md, epidemiology-and-burden.md, jak-inhibitors-and-targeted-therapy.md, overview.md, synovial-immunobiology.md
Gabay C, et al. Tocilizumab versus adalimumab monotherapy: ADACTA. Lancet. 2013;381:1541-1550. (PMID 23515142) Adjacent evidence from biologic-dmards.md, jak-inhibitors-and-targeted-therapy.md, synovial-immunobiology.md
Breedveld FC, et al. PREMIER: adalimumab plus methotrexate versus monotherapies. Arthritis Rheum. 2006;54:26-37. (PMID 16385520) Adjacent evidence from biologic-dmards.md, jak-inhibitors-and-targeted-therapy.md, synovial-immunobiology.md
Klareskog L, et al. Etanercept plus methotrexate versus each alone: TEMPO. Lancet. 2004;363:675-681. (PMID 15001324) Adjacent evidence from biologic-dmards.md, jak-inhibitors-and-targeted-therapy.md, synovial-immunobiology.md
Jones G, et al. Tocilizumab versus methotrexate monotherapy: AMBITION. Ann Rheum Dis. 2010;69:88-96. (PMID 19297346) Adjacent evidence from biologic-dmards.md, jak-inhibitors-and-targeted-therapy.md, synovial-immunobiology.md
Cohen SB, et al. Rituximab after anti-TNF failure: REFLEX. Arthritis Rheum. 2006;54:2793-2806. (PMID 16947627) Adjacent evidence from biologic-dmards.md, jak-inhibitors-and-targeted-therapy.md, synovial-immunobiology.md
Fleischmann R, et al. Abatacept and adalimumab in early RA with poor prognostic factors: AMPLE. Rheumatol Ther. 2019;6:559-571. (PMID 31642045) Adjacent evidence from biologic-dmards.md, jak-inhibitors-and-targeted-therapy.md, synovial-immunobiology.md
Rech J, et al. ARIAA abatacept prevention trial. Lancet. 2024. (PMID 38364841) Adjacent evidence from biologic-dmards.md, clinical-trials-landscape.md, epidemiology-and-burden.md, genetics-environment-and-mucosal-origins.md, jak-inhibitors-and-targeted-therapy.md, overview.md, preclinical-autoimmunity-and-prevention.md, synovial-immunobiology.md
Cope AP, et al. APIPPRA abatacept prevention trial. Lancet. 2024. (PMID 38364839) Adjacent evidence from biologic-dmards.md, clinical-trials-landscape.md, epidemiology-and-burden.md, genetics-environment-and-mucosal-origins.md, jak-inhibitors-and-targeted-therapy.md, overview.md, preclinical-autoimmunity-and-prevention.md, synovial-immunobiology.md
Lee YH, et al. Tocilizumab, rituximab, abatacept and tofacitinib after TNF failure: network meta-analysis. Rheumatol Int. 2016. (PMID 26692536) Adjacent evidence from biologic-dmards.md, jak-inhibitors-and-targeted-therapy.md, synovial-immunobiology.md
Sung YK, et al. Comparative biologic efficacy after TNF-inhibitor failure. Int J Clin Pharmacol Ther. 2022. (PMID 34622767) Adjacent evidence from biologic-dmards.md, jak-inhibitors-and-targeted-therapy.md, synovial-immunobiology.md
Evidence-map records are listed in full below and were live-retrieved from PubMed in this build session.

Open questions

  • Can a rapid synovial assay prospectively improve first-biologic selection?
  • How stable are pathotypes across joints and over treatment? (Schonfeldova 2022, PMID 34559213)
  • Which biomarker defines deep, taper-compatible remission?
  • Can multi-ancestry datasets prevent precision medicine from amplifying inequity?
  • What minimum effect and cost justify biopsy-guided treatment?

References

  1. Humby F, et al. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet. 2021;397:305-317. PMID 33485455
  2. Rivellese F, et al. Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. Nat Med. 2022;28:1256-1268. PMID 35589854
  3. Rivellese F, et al. Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials. Lancet Rheumatol. 2023;5:e648-e659. PMID 38251532
  4. Bhamidipati K, et al. Precision medicine in rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2022;36:101742. PMID 35248489
  5. Atzeni F, et al. Biomarkers in Rheumatoid Arthritis. Isr Med Assoc J. 2017;19:512-516. PMID 28825772
  6. van Heemst J, et al. HLA and rheumatoid arthritis: how do they connect?. Ann Med. 2014;46:304-10. PMID 24813459
  7. Perera J, et al. Clinical Phenotypes, Serological Biomarkers, and Synovial Features Defining Seropositive and Seronegative Rheumatoid Arthritis: A Literature Review. Cells. 2024;13:743. PMID 38727279
  8. de Pablo P, et al. Systematic review of imaging tests to predict the development of rheumatoid arthritis in people with unclassified arthritis. Semin Arthritis Rheum. 2022;52:151919. PMID 34782180
  9. Mandl P, et al. The role of ultrasound and magnetic resonance imaging for treat to target in rheumatoid arthritis and psoriatic arthritis. Rheumatology (Oxford). 2019;58:2091-2098. PMID 31518423
  10. He S, et al. A longitudinal cohort study uncovers plasma protein biomarkers predating clinical onset and treatment response of rheumatoid arthritis. Nat Commun. 2025;16:6692. PMID 40691443
  11. Ling SF, et al. Pharmacogenetics of methotrexate response in rheumatoid arthritis: an update. Pharmacogenomics. 2020;21:3-6. PMID 31849277
  12. Caproli A, et al. Calprotectin as a biomarker in rheumatoid arthritis: the potential predictive value of response to treatment. Bioanalysis. 2023;15:1111-1113. PMID 37584369
  13. Wang D, et al. Diagnostic accuracy of 14-3-3 η protein in rheumatoid arthritis: A meta-analysis. Int J Rheum Dis. 2020;23:1443-1451. PMID 32909672
  14. Curtis JR, et al. Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritis. Rheumatology (Oxford). 2019;58:874-883. PMID 30590790
  15. Bøyesen P, et al. MRI in early rheumatoid arthritis: synovitis and bone marrow oedema are independent predictors of subsequent radiographic progression. Ann Rheum Dis. 2011;70:428-33. PMID 20810395
  16. Takatani A, et al. Prediction of radiographic progression during a treat-to-target strategy by the sequential application of MRI-proven bone marrow oedema and power-Doppler grade ≥2 articular synovitis in rheumatoid arthritis: Retrospective observational study. Mod Rheumatol. 2023;33:708-714. PMID 35856575
  17. Wientjes MHM, et al. Prediction of response to anti-TNF treatment using laboratory biomarkers in patients with rheumatoid arthritis: a systematic review. RMD Open. 2022;8:e002570. PMID 36597975
  18. Gehin JE, et al. Therapeutic serum level for adalimumab in rheumatoid arthritis: explorative analyses of data from a randomised phase III trial. RMD Open. 2024;10:e004888. PMID 39537558
  19. Tasaki S, et al. Multi-omics monitoring of drug response in rheumatoid arthritis in pursuit of molecular remission. Nat Commun. 2018;9:2755. PMID 30013029
  20. de Rooy DP, et al. Smoking as a risk factor for the radiological severity of rheumatoid arthritis: a study on six cohorts. Ann Rheum Dis. 2014;73:1384-7. PMID 24389296
  21. van Steenbergen HW, et al. Association of valine and leucine at HLA-DRB1 position 11 with radiographic progression in rheumatoid arthritis, independent of the shared epitope alleles but not independent of anti-citrullinated protein antibodies. Arthritis Rheumatol. 2015;67:877-86. PMID 25580908
  22. Archer R, et al. Assessing prognosis and prediction of treatment response in early rheumatoid arthritis: systematic reviews. Health Technol Assess. 2018;22:1-294. PMID 30501821
  23. Jang S, et al. Rheumatoid Arthritis: Pathogenic Roles of Diverse Immune Cells. Int J Mol Sci. 2022;23:905. PMID 35055087
  24. Cheng L, et al. New Insights From Single-Cell Sequencing Data: Synovial Fibroblasts and Synovial Macrophages in Rheumatoid Arthritis. Front Immunol. 2021;12:709178. PMID 34349767
  25. Knab K, et al. Synovial Macrophage and Fibroblast Heterogeneity in Joint Homeostasis and Inflammation. Front Med (Lausanne). 2022;9:862161. PMID 35547214
  26. Kemble S, et al. Critical Role of Synovial Tissue-Resident Macrophage and Fibroblast Subsets in the Persistence of Joint Inflammation. Front Immunol. 2021;12:715894. PMID 34539648
  27. Pap T, et al. Fibroblast biology. Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthritis Res. 2000;2:361-7. PMID 11094449
  28. Komatsu N, et al. Mechanisms of joint destruction in rheumatoid arthritis - immune cell-fibroblast-bone interactions. Nat Rev Rheumatol. 2022;18:415-429. PMID 35705856
  29. Matsuda K, et al. New Insights into the Role of Synovial Fibroblasts Leading to Joint Destruction in Rheumatoid Arthritis. Int J Mol Sci. 2023;24:5173. PMID 36982247
  30. Lipsky PE, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343:1594-602. PMID 11096166
  31. Gabay C, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013;381:1541-50. PMID 23515142
  32. Breedveld FC, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26-37. PMID 16385520
  33. Klareskog L, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363:675-81. PMID 15001324
  34. Jones G, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69:88-96. PMID 19297346
  35. Cohen SB, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793-806. PMID 16947627
  36. Fleischmann R, et al. Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE). Rheumatol Ther. 2019;6:559-571. PMID 31642045
  37. Rech J, et al. Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial. Lancet. 2024;403:850-859. PMID 38364841
  38. Cope AP, et al. Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial. Lancet. 2024;403:838-849. PMID 38364839
  39. Lee YH, et al. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials. Int J Rheum Dis. 2016;19:1103-1111. PMID 26692536
  40. Sung YK, et al. Comparative efficacy and safety of biologic agents in patients with active rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials. Int J Clin Pharmacol Ther. 2022;60:13-23. PMID 34622767
  41. Schonfeldova B, et al. Synovial single-cell heterogeneity, zonation and interactions: a patchwork of effectors in arthritis. Rheumatology (Oxford). 2022;61:913-925. PMID 34559213